From IND to NDA: Understanding the FDA Regulatory Pathway for Peptide Therapeutics
Peptide therapeutics occupy an unusual regulatory position. Structurally, they sit between small-molecule drugs and large biological proteins — complex enough to require sophisticated manufacturing controls, yet often simple enough to be synthesized chemically rather than expressed through living cell systems. This structural ambiguity has shaped a regulatory framework that draws from both pharmaceutical and biologic traditions, with specific guidance documents addressing the unique challenges peptides present at every stage of development.
For researchers, clinicians, and informed observers, understanding the formal pathway from preclinical investigation to approved therapeutic is not merely procedural knowledge. It is the foundation for interpreting what any given peptide compound is legally and scientifically permitted to claim — and what it cannot.
The Foundational Distinction: Research Compounds, IND-Enabled Compounds, and Approved Therapeutics
The regulatory status of a peptide compound determines, with considerable precision, what claims may be made about it and how it may be used. Three categories are relevant to most discussions of peptide science.
A research compound is a substance that has not received FDA authorization for clinical investigation in humans. It may have extensive preclinical data — animal studies, in vitro assays, mechanistic research — but it has not cleared the threshold required to be administered to human subjects in a formal clinical context. Research compounds may be studied in laboratory settings, and preclinical findings may be published, but no therapeutic claims are warranted by their status.
An IND-enabled compound has received FDA authorization under an Investigational New Drug application, governed by 21 CFR Part 312 [2]. This authorization permits the compound to be administered to human subjects within a defined clinical protocol. IND status does not constitute approval; it constitutes permission to investigate. The compound remains investigational, and its safety and efficacy profile in humans is, by definition, still being established.
An FDA-approved therapeutic has completed the full review process — including Phase I, II, and III clinical trials — and has received approval through a New Drug Application (NDA) or Biologics License Application (BLA). Approved peptide therapeutics such as exenatide, octreotide, and liraglutide carry documented indications, labeling requirements, and post-market surveillance obligations that research compounds do not [3].
This tripartite distinction is not merely administrative. It defines the scientific and legal basis for any claim made about a peptide compound's effects in humans.
The IND Application: Structure and Peptide-Specific Requirements
The IND application is the formal instrument through which a sponsor — typically a pharmaceutical company, academic institution, or research organization — requests FDA authorization to begin human clinical trials. Under 21 CFR Part 312, the application must contain three primary components: chemistry, manufacturing, and controls (CMC) data; pharmacology and toxicology summaries; and a clinical protocol with investigator information [2].
Chemistry, Manufacturing, and Controls
For peptide compounds, the CMC section is frequently the most technically demanding component of an IND submission. The FDA's expectations for peptide CMC data reflect the compound class's particular vulnerabilities: susceptibility to degradation, aggregation, and racemization; sensitivity to temperature, pH, and light; and the complexity of ensuring batch-to-batch consistency in synthesis [1].
The CMC section must establish the identity, purity, and potency of the peptide, along with a description of the manufacturing process and its controls. For synthetic peptides, this typically involves documenting solid-phase peptide synthesis parameters, purification methods (commonly high-performance liquid chromatography), and analytical characterization techniques including mass spectrometry and amino acid analysis [1]. For longer peptides or those produced through recombinant means, additional characterization of higher-order structure may be required.
Stability data are a recurring point of regulatory scrutiny. The IND must demonstrate that the compound is stable under the proposed storage and administration conditions for the duration of the clinical trial. Early-phase INDs often include only short-term stability data, with commitments to provide longer-term data as the program advances — a common source of regulatory deficiency if those commitments are not met on schedule.
Pharmacology and Toxicology
The pharmacology and toxicology section summarizes preclinical data sufficient to establish a reasonable basis for initiating human studies. For peptides, this typically includes in vitro receptor binding or enzyme inhibition studies, pharmacokinetic data in at least one animal species, and toxicology studies conducted under Good Laboratory Practice (GLP) conditions.
The FDA applies a risk-based approach to preclinical data requirements. A first-in-human study of a novel peptide with an unknown mechanism will require more extensive preclinical characterization than a study of a peptide analog closely related to an approved compound. The agency's guidance on preclinical safety evaluation provides a framework for determining which toxicology studies are expected prior to Phase I, Phase II, and Phase III initiation respectively.
Clinical Protocol Design
The clinical protocol must describe the study design, patient population, dosing regimen, safety monitoring plan, and stopping rules. For peptide compounds, protocol design must account for the route of administration — subcutaneous injection is common for peptides due to poor oral bioavailability — and the potential for injection-site reactions, which require specific monitoring provisions.
The IND also requires designation of a clinical investigator and a statement of the investigator's qualifications. All human subjects research conducted under an IND must comply with FDA regulations on informed consent and institutional review board oversight.
Clinical Trial Phases: Regulatory Expectations at Each Stage
Once an IND is active, the clinical development program proceeds through three phases, each with distinct regulatory expectations and decision points.
Phase I: Safety and Pharmacokinetics
Phase I trials are primarily designed to assess safety, tolerability, and pharmacokinetics in a small number of subjects — typically 20 to 100 healthy volunteers or, in oncology, patients with the target disease. For peptide compounds, Phase I endpoints commonly include characterization of absorption, distribution, metabolism, and excretion (ADME), identification of dose-limiting toxicities, and preliminary assessment of immunogenicity.
Immunogenicity — the potential for a peptide to elicit an anti-drug antibody response — is a peptide-specific regulatory concern that the FDA addresses in dedicated guidance [6]. Anti-drug antibodies can neutralize therapeutic activity, alter pharmacokinetics, or, in rare cases, trigger serious immune reactions. Phase I protocols for peptide compounds are expected to include immunogenicity assays, and the results inform both subsequent trial design and, ultimately, product labeling.
Phase II: Proof of Concept and Dose Selection
Phase II trials expand the subject population to several hundred patients with the target condition and are designed to provide preliminary evidence of efficacy alongside continued safety assessment. Dose selection is a primary objective: Phase II data establish the dose or dose range that will be carried into the pivotal Phase III program.
For peptide therapeutics, Phase II protocols must address formulation stability under real-world conditions, patient-reported outcomes related to the route of administration, and, where relevant, the relationship between pharmacokinetic exposure and pharmacodynamic response. The FDA may request a Type B meeting with the sponsor at the end of Phase II — an End-of-Phase-2 meeting — to align on the Phase III design before the sponsor commits to a large, expensive pivotal program.
Phase III: Pivotal Efficacy and Safety
Phase III trials are the pivotal studies on which an NDA or BLA approval decision is primarily based. These are typically randomized, controlled trials enrolling hundreds to thousands of patients, powered to demonstrate statistically significant efficacy on pre-specified primary endpoints while characterizing the safety profile with sufficient precision to support product labeling.
For peptide therapeutics, Phase III programs must also include studies sufficient to support labeling in special populations — patients with renal or hepatic impairment, elderly patients, and, where applicable, pediatric populations. The FDA's pediatric research requirements under the Pediatric Research Equity Act may mandate pediatric studies as a condition of approval or post-approval commitment.
NDA and BLA Submission: Compiling the Approval Dossier
The NDA (for chemically synthesized peptides) or BLA (for peptides produced through biological processes) is the comprehensive submission through which a sponsor requests approval to market a therapeutic. The distinction between NDA and BLA pathways for peptides has been a subject of regulatory evolution; the Biologics Price Competition and Innovation Act of 2009 shifted certain peptides to the BLA pathway, though the practical implications depend on the specific compound and its manufacturing process.
The submission compiles all data generated across the development program into a structured dossier organized according to the Common Technical Document (CTD) format, which is accepted by FDA, the European Medicines Agency (EMA), and other ICH member authorities. The CTD contains five modules covering administrative information, quality (CMC), nonclinical study reports, clinical study reports, and clinical overview.
The FDA's standard review timeline is twelve months from the date of filing acceptance, with a six-month priority review available for compounds that address unmet medical needs. The agency issues a Complete Response Letter if the application is not approvable as submitted, detailing the deficiencies that must be addressed before approval can be granted.
Expedited Pathways: Accelerated Approval, Breakthrough Therapy, and Fast-Track
The FDA maintains several expedited development and review programs for compounds that address serious conditions and demonstrate preliminary evidence of meaningful benefit. These programs are relevant to peptide therapeutics addressing oncology, rare diseases, and other areas of high unmet need.
Fast-Track designation is available for compounds intended to treat serious conditions and that demonstrate potential to address unmet medical need. It facilitates more frequent interactions with the FDA during development and allows rolling NDA submission — submitting completed sections of the application before the full dossier is ready.
Breakthrough Therapy designation is granted when preliminary clinical evidence indicates that the compound may demonstrate substantial improvement over available therapies on a clinically significant endpoint. It carries the benefits of Fast-Track designation plus more intensive FDA guidance during development.
Accelerated Approval permits approval based on a surrogate endpoint reasonably likely to predict clinical benefit, with a requirement for post-approval confirmatory trials. Several peptide and peptide-related compounds have utilized this pathway in oncology settings.
Post-Approval Obligations and the Significance of Approved Status
Approval is not the conclusion of regulatory oversight; it is a transition to a different set of obligations. Approved peptide therapeutics are subject to pharmacovigilance requirements, including expedited reporting of serious unexpected adverse events and periodic safety update reports. Manufacturers must maintain compliance with current Good Manufacturing Practice (cGMP) regulations, and any changes to the approved manufacturing process, formulation, or labeling require prior FDA review.
Product labeling — the prescribing information — defines the approved indication, dosing, contraindications, warnings, and the clinical data supporting each claim. This labeling is the legal boundary of what may be claimed about an approved therapeutic in promotional materials. Claims beyond the approved labeling constitute off-label promotion, which is subject to FDA enforcement.
This regulatory structure is what fundamentally distinguishes an approved peptide therapeutic from a research compound. An approved product carries a defined, evidence-supported indication backed by a complete clinical data package reviewed by the agency. A research compound, regardless of the volume of preclinical data supporting it, has not cleared that threshold.
International Harmonization: FDA, EMA, and ICH Alignment
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has developed guidelines that align regulatory expectations across major markets, including the United States, European Union, Japan, and increasingly other jurisdictions. For peptide therapeutics, relevant ICH guidelines address quality (Q6B for biological and peptide characterization), safety (S6 for preclinical safety of biotechnology-derived pharmaceuticals), and efficacy (E6 for Good Clinical Practice).
Despite this harmonization, meaningful differences persist between FDA and EMA approaches to peptide regulation, particularly regarding the NDA versus BLA classification question and immunogenicity assessment requirements. Sponsors seeking simultaneous global development programs typically engage in parallel scientific advice procedures with both agencies to identify and reconcile these differences early in development.
Common Regulatory Deficiencies in Peptide INDs
Analysis of FDA Complete Response Letters and published regulatory case studies reveals recurring patterns of deficiency in peptide IND submissions and NDA applications [3]. Manufacturing scalability is a persistent challenge: processes that produce high-purity peptide at laboratory scale frequently encounter yield, purity, or consistency problems when scaled to clinical or commercial manufacturing volumes. Sponsors who have not demonstrated scalability before IND submission may face clinical holds or manufacturing-related delays.
Stability data gaps represent another common deficiency. The FDA expects stability data under International Conference on Harmonisation conditions (25°C/60% relative humidity for long-term; 40°C/75% relative humidity for accelerated), and submissions that rely on extrapolated or incomplete stability data are vulnerable to requests for additional information that can extend review timelines significantly.
Preclinical-to-clinical translation challenges are inherent to peptide pharmacology. Species differences in receptor expression, peptide metabolism, and immunogenicity mean that animal study results do not always predict human outcomes with precision. Sponsors who over-interpret preclinical data in their IND rationale — particularly regarding expected efficacious doses — may encounter dose-selection problems in Phase II that require additional studies and extend development timelines.
Conclusion
The FDA regulatory pathway for peptide therapeutics is a structured, evidence-driven process designed to establish, with scientific rigor, whether a compound is safe and effective for a defined human use. Each stage — from IND application through clinical phases to NDA review — represents a formal threshold that a compound must clear before its status advances. The distinction between a research compound, an IND-enabled investigational compound, and an approved therapeutic is not semantic; it reflects the cumulative weight of evidence the regulatory system has evaluated and accepted. Understanding this framework is foundational to interpreting the scientific and legal standing of any peptide compound in development or on the market.